Loading...
•
Mar 31, 2023
Mersana Q1 2023 Earnings Report
Mersana announced its Q1 2023 financial results and provided a business update.
Key Takeaways
Mersana Therapeutics reported its first quarter 2023 financial results, highlighting the anticipation of topline data for UPLIFT and a comprehensive development plan for UpRi. The company is focused on ADC innovation and advancing its pipeline, supported by a solid financial position.
Topline data for UPLIFT is expected in the near term.
A comprehensive development plan aims to establish UpRi as a foundational medicine in ovarian cancer.
Mersana continues to focus on ADC innovation using its proprietary platforms.
The company is advancing a pipeline of wholly owned assets and programs with several collaborators.